

JONAS SALK PUBLICATIONS
Complete Listing: 1938 - 1994

1. Salk, J. --- Method for separation of micro-organisms from large quantities of broth culture. *Proc. Soc. Exp. Biol. Med.* 38: 228-30, 1938.
2. Salk, J., Lavin, G. I., and Francis, T. Jr. --- The antigenic potency of epidemic influenza virus following inactivation by ultraviolet radiation. *J. Exp. Med.* 72(6): 729-45, 1940.
3. Salk, J. --- Partial purification of the virus of epidemic influenza by adsorption on calcium phosphate. *Proc. Soc. Exp. Biol. Med.* 46: 709-12, 1941.
4. Francis, T. Jr. and Salk, J. --- A simplified procedure for the concentration and purification of influenza virus. *Science* 96(2500): 499-500, 1942.
5. Salk, J., Menke, W. J., and Francis, T. Jr. --- Identification of influenza virus type A in current outbreak of respiratory disease. *JAMA* 124: 93, 1944.
6. Francis, T. Jr., Salk, J., Pearson, H. E., and Brown, P. N. --- Protective effect of vaccination against induced influenza A. *Proc. Soc. Exp. Biol. Med.* 55: 104-05, 1944.
7. Salk, J., Pearson, H. E., Brown, P. N., and Francis, T. Jr. --- Protective effect of vaccination against induced influenza B. *Proc. Soc. Exp. Biol. Med.* 55: 106-07, 1944.
8. Francis, T. Jr., Pearson, H. E., Salk, J., and Brown, P. N. --- Immunity in human subjects artificially infected with influenza virus type B. *Amer. J. Publ. Hlth.* 34(4): 317-34, 1944.
9. Joint Report with Members of the Commission on Influenza, Board for the Investigation and Control of Influenza and Other Epidemic Diseases in the Army, Preventive Medicine Service, Office of the Surgeon General, United States Army. -- A clinical evaluation of vaccination against influenza. *JAMA* 124: 982-85, 1944.
10. Salk, J. --- A simplified procedure for titrating hemagglutinating capacity of influenza virus and the corresponding antibody. *J. Immunol.* 49(2): 87-98, 1944.
11. Salk, J. --- The immunizing effect of calcium phosphate adsorbed influenza virus. *Science* 101(2614): 122-24, 1945.
12. Francis, T. Jr., Salk, J., Pearson, H. E., and Brown, P. N. --- Protective effect of vaccination against induced influenza A. *J. Clin. Invest.* 24(4): 536-46, 1945.

13. Francis, T. Jr., Salk, J., Pearson, H. E., and Brown, P. N. --- Protective effect of vaccination against induced influenza B. *J. Clin. Invest.* 24(4): 547-53, 1945.
14. Salk, J., Menke, W. J. Jr., and Francis, T. Jr. --- A clinical, epidemiological and immunological evaluation of vaccination against epidemic influenza. *Amer. J. Hyg.* 42(1): 57-93, 1945.
15. Salk, J., Pearson, H. E., Brown, P. N., Smyth, C. J., and Francis, T. Jr. --- Immunization against influenza with observations during an epidemic of influenza A one year after vaccination. *Amer. J. Hyg.* 42(3): 307-22, 1945.
16. Salk, J. --- Laboratory methods used for the recognition of influenza. *Bull. U.S. Army Med. Dept.* 5(1): 32-36, 1946.
17. Francis, T. Jr., Salk, J., and Brace, W. M. --- The protective effect of vaccination against epidemic influenza B. *JAMA* 131: 275-78, 1946.
- 17a. Salk, J. --- Influenza in Europe during the winter of 1945-46. *J. Bacteriol.* 51: 632, 1946.
18. Salk, J. and Francis, T. Jr. --- Immunization against influenza. *Ann. Int. Med.* 25(3): 443-52, 1946.
19. Francis, T. Jr. and Salk, J. --- A consideration of vaccination against influenza. *Trans. Assn. Amer. Physician* 59: 197-204, 1946.
20. Salk, J. --- Variation in influenza viruses. A study of heat stability of the red cell agglutinating factor. *Proc. Soc. Exp. Biol. Med.* 63: 134-39, 1946.
21. Salk, J. --- Effect of formalin in increasing heat stability of influenza virus hemagglutinin. *Proc. Soc. Exp. Biol. Med.* 63: 140-43, 1946.
22. Salk, J. --- The control of influenza by immunization. *The J. Lancet (Minn.)* 67(1): 18-23, 1947.
23. Salk, J. --- Reactions to influenza virus vaccines. *JAMA* 134(4): 393, 1947.
24. Blaskovic, D. and Salk, J. --- A method applicable to the standardization of influenza virus vaccines. *Proc. Soc. Exp. Biol. Med.* 65: 352-59, 1947.
25. Francis, T. Jr., Salk, J., and Quilligan, J. J. Jr. --- Experience with vaccination against influenza in the spring of 1947. *Amer. J. Publ. Hlth.* 37(8): 1013-16, 1947.
26. Salk, J. --- Influenza. In *Handbook of Communicable Diseases*, 2nd Ed., F. H. Top and Collaborators (St. Louis: C. V. Mosby & Co., 1947), pp. 626-45.

27. Salk, J. --- Studies on the antigenicity, in man, of calcium phosphate adsorbed influenza virus; with comments on the questions of dose of virus needed in vaccines for human use. *J. Immunol.* 57(4): 301-21, 1947.
28. Salk, J. --- Reactions to concentrated influenza virus vaccines. *J. Immunol.* 58(4): 369-95, 1948.
29. Salk, J. --- A plastic plate for use in tests involving virus hemagglutination and other similar reactions. *Science* 108(2818): 749, 1948.
- 29a. Salk, J. --- Studies on calcium phosphate adsorbed influenza virus. In Report of the Proceedings of the Fourth International Congress of Microbiology (Copenhagen, 1949), p. 298.
30. Salk, J. and Suriano, P. C. --- Importance of antigenic composition of influenza virus vaccine in protecting against the natural disease. Observations during the winter of 1947-48. *Amer. J. Publ. Hlth.* 39(3): 345-55, 1949.
31. Salk, J., Laurent, A. M., and McGinnis, R. C. --- Differences in antigenic capacity among influenza virus strains. *Fed. Proc.* 8(1), March 1949.
- 31a. Salk, J. and Lynch, M. P. --- Unusual serological findings in a group of cases of pneumococcal pneumonia associated with the presence of influenza virus in the sputum. *J. Clin. Invest.* 28(4): 808, 1949.
32. Salk, J. --- Viral and rickettsial infections of the lung. Comments on the problem of specific therapy. *Penn. Med. J.* 52: 1650-52, 1949.
33. Salk, J. and Youngner, J. S. --- Antibody in yolk of eggs and in serum from hens inoculated with viruses of influenza and poliomyelitis. *Fed. Proc.* 9(1): 391, 1950.
34. Bennett, B. L. and Salk, J. --- Immunologic comparison of different laboratory lines of the Lansing strain of poliomyelitis virus. *J. Immunol.* 66(2): 277-81, 1951.
35. Salk, J. and Bennett, B. L. --- Evidence for dissociation of titer of infectious and antigenic activity in the preparation of the Lansing strain of poliomyelitis virus. *J. Immunol.* 66(2): 283- 86, 1951.
- 35a. Salk, J., Bailey, M. L., and Laurent, A. M --- A safe immunologic adjuvant for enhancing the height and persistence of antibody response to influenza virus vaccines in man. *J. Clin. Invest.* 30(6): 699 (abstract), 1951.
36. Salk, J., Laurent A. M, and Bailey, M. L. --- Direction of research on vaccination against influenza--new studies with immunological adjuvants. *Amer. J. Publ. Hlth.* 41(6): 669-77, 1951.

37. Salk, J., Lewis, L. J., Youngner, J. S., and Bennett, B. L. --- The use of adjuvants to facilitate studies on the immunologic classification of poliomyelitis viruses. *Amer. J. Hyg.* 54(2): 157-73, 1951.
38. Salk, J., Bennett, B. L., Lewis, L. J., and Youngner, J. S. --- Immunologic classification of poliomyelitis viruses. III. Results obtained with the method of neutralization with prototype antisera. A. Preparation of antiserum pools. *Amer. J. Hyg.* 54(2): 216-29, 1951.
- 38a. Salk, J., Lewis, L. J., Bennett, B. L., and Youngner, J. S. --- Immunologic classification of poliomyelitis viruses. III. Results obtained with the method of neutralization with prototype antisera. B. Studies from the University of Pittsburgh on Twenty-Three Strains. *Amer. J. Hyg.* 54(2): 230-42, 1951.
- 38b. Salk, J., Youngner, J. S., Lewis, L. J., and Bennett, B. L. --- Immunologic classification of poliomyelitis viruses. IV. Results of typing by neutralization of prototype viruses with antiserum produced by vaccinating monkeys with unknown strain and an adjuvant. *Amer. J. Hyg.* 54(2): 255-67, 1951.
39. Salk, J. --- A critique of serologic methods for the study of influenza viruses. *Archiv. Gesamte Virusforsch.* 4(4): 476-84, 1951.
40. Youngner, J. S., Ward, E. N., and Salk, J. --- Studies on poliomyelitis viruses in cultures of monkey testicular tissues. I. Propagation of virus in roller tubes. *Amer. J. Hyg.* 55(2): 291-300, 1952.
41. Youngner, J. S., Ward, E. N., and Salk, J. --- Studies on poliomyelitis viruses in cultures of monkey testicular tissue. II. Differences among strains in tissue culture infectivity with preliminary data on the quantitative estimation of virus and antibody. *Amer. J. Hyg.* 55(2): 301-22, 1952.
42. Salk, J. and Laurent, A. M. --- The use of adjuvants in studies on influenza immunization. I. Measurements in monkeys of the dimensions of antigenicity of virus-mineral oil emulsions. *J. Exp. Med.* 95(5): 429-47, 1952.
43. Salk, J., Bailey, M. L., and Laurent, A. M. --- The use of adjuvants in studies on influenza immunization. II. Increased antibody formation in human subjects inoculated with influenza virus vaccine in a water-in-oil emulsion. *Amer. J. Hyg.* 55(3): 439-56, 1952.
44. Youngner, J. S., Lewis, L. J., Ward, E. N., and Salk, J. --- Studies on poliomyelitis viruses in cultures of monkey testicular tissue. III. Isolation and immunologic identification of poliomyelitis viruses from fecal specimens by means of roller tube cultures. *Amer. J. Hyg.* 55(3): 347-56, 1952.

45. Youngner, J. S., Ward, E. N., and Salk, J. --- Effect of 5-amino-7-hydroxy-1H-v-Triazolo (d) pyrimidine on growth and development of the chick embryo. *Proc. Soc. Exp. Biol. Med.* 75: 157-61, 1950.
46. Salk, J. --- An interpretation of the significance of the influenza virus variation for the development of an effective vaccine. *Bull. N.Y. Acad. Med.* 28(11): 748-65, 1952.
47. Salk, J., Lewis, L. J., Bennett, B. L., and Youngner, J. S. --- Immunization of monkeys with poliomyelitis viruses grown in cultures of monkey testicular tissue. *Fed. Proc.* 11(1): 480 (abstract), 1952.
48. Youngner, J. S., Salk, J., and Ward, E. N. --- A study of factors important for the application of roller tube cultures of monkey testicular tissue to quantitative immunologic studies with poliomyelitis viruses. *Fed. Proc.* 11(1): 486 (abstract), 1952.
49. Salk, J., Bennett, B. L., Youngner, J. S., and Lewis, L. J. --- Destruction of infectivity and retention of antigenicity of poliomyelitis viruses contained in tissue culture fluids. *Bact. Proc.:* 102 (abstract), March 1952.
50. Salk, J., Bennett, B. L., Lewis, L. J., Ward, E. N., and Youngner, J. S. --- Studies in human subjects on active immunization against poliomyelitis. 1. A preliminary report of experiments in progress. *JAMA* 151(13): 1081-98, 1953.
51. Salk, J., Contakos, M., Laurent, A. M., Sorensen, M., Rapalski, A. J., Simmons, I. H., and Sandberg, H. --- Use of adjuvants in studies on influenza immunization. 3. Degree of persistence of antibody in human subjects two years after vaccination. *JAMA* 151(14): 1169-75, 1953.
52. Salk, J. --- Immunization against poliomyelitis. *Pediatrics Clinics of N. A.* 1(1A): 49-51, 1953.
53. Salk, J. --- Principles of immunization as applied to poliomyelitis and influenza. *Amer. J. Publ. Hlth.* 43(11): 1384-98, 1953.
54. Salk, J. --- Mechanisms of convalescent immunity and how it may be simulated. In *The Dynamics of Virus and Rickettsial Infections*, F. W. Hartman, F. L. Horsfall, Jr., J. G. Kidd, eds. (New York: Blakiston, 1954), pp. 219-43.
55. Salk, J. --- Recent studies on immunization against poliomyelitis. *Pediatrics* 12(5): 471-82, 1953.
56. Salk, J., Krech, U., Youngner, J. S. Bennett, B. L., Lewis, L. J., and Bazeley, P. L. - -- Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. *Amer. J. Publ. Hlth.* 44(5): 563-70, 1954.

57. Salk, J., Bazeley, P. L., Bennett, B. L., Krech, U., Lewis, L. J., Ward, E.N., and Youngner, J. S. --- Studies in human subjects on active immunization against poliomyelitis. 2. A practical means for inducing and maintaining antibody formation. *Amer. J. Publ. Hlth.* 44(8): 994-1009, 1954.
58. Salk, J., Youngner, J. S., and Ward, E. N. --- Use of color change of phenol red as the indicator in titrating poliomyelitis virus or its antibody in a tissue-culture system. *Amer. J. Hyg.* 60(2): 214-30, 1954.
59. Salk, J., Lewis, L. J., Bennett, B. L., Ward, E. N., Krech, U., Youngner, J. S., and Bazeley, P. L. --- Antigenic activity of poliomyelitis vaccines undergoing field test. *Amer. J. Publ. Hlth.* 45(2): 151-62, 1955.
60. Salk, J. --- Present status of the problem of vaccination against poliomyelitis. *Amer. J. Publ. Hlth.* 45(3): 285-97, 1955.
61. Salk, J. --- Studies with non-infectious poliomyelitis virus vaccines. In *Poliomyelitis [Papers and Discussions Presented at the Third International Poliomyelitis Conference]* (Philadelphia: J. B. Lippincott Co., 1955), pp. 167-85.
- 61a. Salk, J. --- Vaccines for poliomyelitis. *Sci. Amer.* 192(4): 42-44, 1955.
62. Salk, J. --- Vaccination against paralytic poliomyelitis--performance and prospects. *Amer. J. Publ. Hlth.* 45(5): 575-96, 1955.
63. Salk, J. --- Considerations in the preparation and use of poliomyelitis virus vaccine. *JAMA* 158: 1239-48, 1955.
64. Salk, J. --- A concept of the mechanism of immunity for preventing paralysis in poliomyelitis. *Ann. N.Y. Acad. Sci.* 61: 1023-36, 1955.
65. Salk, J. --- Poliomyelitis vaccination--practicalities for the practicing physician. *Penn. Med. J.* 58: 1321-24, 1955.
66. Salk, J. --- Poliomyelitis vaccine in the fall of 1955. *Amer. J. Publ. Hlth.* 46(1): 1-14, 1956.
- 66a. Bodian, D., Francis, T. Jr., Larson, C., Salk, J., Shope, R. E., Smadel, J. E., and Shannon, J. A. --- Interim Report, Public Health Service Technical Committee on Poliomyelitis Vaccine. *JAMA* 159: 1444-47, 1955.
67. Youngner, J. S. and Salk, J. --- Antibody titer for seven different type I strains of poliomyelitis virus in children vaccinated with the Mahoney strain. *Amer. J. Hyg.* 63(2): 198-203, 1956.

68. Salk, J., Bennett, B. L., Lewis, L. J., and Yurochko, F. --- Effect of prolonged formaldehyde treatment upon antigenic activity of different strains of poliomyelitis viruses. *Fed. Proc.* 15(1): 611 (abstract), 1956.
69. Salk, J. --- Requirements for persistent immunity to poliomyelitis. *Trans. Assn. Amer. Phys.* 69: 105-14, 1956.
- 69a. Technical Committee on Poliomyelitis Vaccine and Subcommittee on Monkey Safety Test --- The monkey safety test for poliomyelitis vaccine. *Amer. J. Hyg.* 64(1): 104-37, 1956.
70. Neva, F. A. and Salk, J. --- Serial urinary addis counts in patients inoculated repeatedly with poliomyelitis vaccine prepared from monkey kidney tissue cultures. *J. Lab. & Clin. Med.* 46(1): 21-27, 1955.
71. Salk, J. --- Antigenic potency of poliomyelitis--influence on degree and duration of vaccine effect. *JAMA* 162: 1451-59, 1956.
72. Salk, J. --- Poliomyelitis vaccination in the fall of 1956. *Amer. J. Publ. Hlth.* 47(1): 1-18, 1957.
73. Salk, J. --- Viral and cellular factors pertinent to the control of paralytic poliomyelitis with a non-infectious vaccine. *N.Y. Acad. Sci. (Special Publication)* 5: 77-89, 1957.
74. Salk, J. --- Basic principles underlying immunization against poliomyelitis with a non-infectious vaccine. In *Poliomyelitis [Papers and Discussions Presented at the 4th International Poliomyelitis Conference]* (Philadelphia: J. B. Lippincott Co., 1958), pp. 66-76; pp. 289-92 (Discussion--Cultured Mammalian Cells); pp. 389-91 (Discussion--Neutralization Tests).
75. Salk, J. and Ward, E. N. --- Some characteristics of a continuously propagating cell derived from monkey heart tissue. *Science* 126(3287): 1338-39, 1957.
76. Salk, J. and Rapalski, A. J. --- Evaluation of influenza vaccine in an explosive epidemic of mixed etiology. *U.S. Armed Forces Med. J.* 9(4): 469- 78, 1958.
77. Salk, J. --- How many injections of poliomyelitis vaccine for effective and durable immunity? *JAMA* 167: 1-7, 1958.
78. Salk, J. --- Current trends in poliovirus activity. *Mod. Med.* 26(13): 83-88, 1958.
79. Salk, J. --- Poliomyelitis vaccine preparation and administration. Analysis of basic premises and current practices. *JAMA* 169: 1829-38, 1959.

80. Salk, J. --- Preconceptions about vaccination against paralytic poliomyelitis. *Ann. Int. Med.* 50(4): 843-61, 1959.
81. Salk, J. --- Vaccination against poliomyelitis: an ounce of prevention. *Royal Soc. Hlth. J.* 79(4): 310-23, 1959.
82. Salk, J. --- Poliomyelitis control. In *Viral and Rickettsial Infections of Man*, 3rd ed., T. M. Rivers and F. L. Horsfall, Jr., eds. (Philadelphia: J. B. Lippincott Co., 1959), pp. 499-518.
83. Salk, J. and Gori, J. B. --- A review of theoretical, experimental, and practical considerations in the use of formaldehyde for the inactivation of poliovirus. *Ann. N.Y. Acad. Sci.* 83(4): 609-37, 1960.
84. Salk, J. --- Persistence of immunity after administration of formalin-treated poliovirus vaccine. *Lancet* ii: 715-23, 1960.
85. Salk, J. --- Viral diseases; their control by immunologic means. *Postgrad. Med.* 30(2): 99-110, 1961.
86. Salk, J. --- Biological basis of disease and behavior. *Perspectives in Biol. & Med.* 5(2): 198-206, 1962.
87. Salk, J. --- Biology in the future. *Perspectives in Biol. & Med.* 5(4): 423-31, 1962.
- 87a. Salk, J. --- Infectious molecules and human disease. *Annual Health Conference Lectureships, Vol. I* (Albany, NY: Health Education Service, 1962).
88. Salk, J. --- Mechanisms of immunity in virus infections. In *Recent Progress in Microbiology* [8th International Congress for Microbiology] (Toronto: University of Toronto Press, 1963), pp. 388-98.
89. Salk, J. --- Awareness of order. The 1963 Edison Science Youth Day Address, Thomas Alva Edison Foundation, Los Angeles, 11 Feb. 1963.
90. Salk, J. --- Polio immunization and the herd effect. *Zentrbl. Bakteriol. Abst.* 1, Orig. 191: 68-83, 1963.
- 90a. Klone, W., Kulemann, H., Ward, E. N., and Salk, J. --- Fusion of LLC-MK2 tissue culture cells induced by measles virus. *Archiv. Gesamte Virusforsch.* XIX(2): 91-109, 1966.
91. Eylar, E. H., Salk, J., Beveridge, G. C., and Brown, L. V. --- Experimental allergic encephalomyelitis: an encephalitogenic basic protein from bovine myelin. *Arch. Biochem. Biophys.* 132(1): 34-38, 1969.

92. Salk, J. --- Narcissism and responsibility in science and in man. The Robert Kennedy Duncan Memorial Lecture, Carnegie-Mellon University, 9 May 1969.
93. Salk, J. --- Immunological paradoxes: theoretical considerations in the rejection or retention of grafts, tumors, and normal tissue. *Ann. N.Y. Acad. Sci.* 164(2): 365-80, 1969.
94. Salk, J. --- The restless spirit of Thomas Francis, Jr., still lives: the unresolved problems of recurrent influenza epidemics. *Arch. Environ. Hlth.* 21: 273-75, 1970.
95. Salk, J. --- The world we will live in. *Ann. N.Y. Acad. Sci.* 184: 136-42, 1971.
96. Salk, J. --- What do we mean by health? *J. Amer. School Hlth.* 42(10): 582-84, 1972.
97. Salk, J. and Salk, D. --- Control of influenza and poliomyelitis with killed virus vaccines. *Science* 195(4281): 834-47, 1977.
98. Salk, J. and Salk, D. --- Vaccination against poliomyelitis. In *New Trends and Developments in Vaccines*, A. Voller and H. Friedman, eds. (Lancashire, Eng.: MTP Press, 1978), pp. 117-53.
99. Salk, J., Cohen, H., Fillastre, C., Stoeckel, P., Rey, J.-L., Schlumberger, M., Nicolas, A., van Steenis, G., van Wezel, A. L., Triau, R., Saliou, P., Barry, L. F., Moreau, J.-P., and Merieux, C. --- Killed poliovirus antigen titration in humans. *Dev. Biol. Stand.* 41: 119-32, 1978.
100. Salk, J. and Salk, D. --- Principles of vaccinology in the control of virus diseases: poliomyelitis. In *Viruses and Environment*, E. Kurstak and K. Maramorosch, eds. (New York: Academic Press, 1978), pp. 451-96.
- 100a. Salk, Jonas --- Anticipating tomorrow's schools. In *Educational Reform for a Changing Society: Anticipating Tomorrow's Schools*, L. Rubin, ed. (Boston: Allyn and Bacon, Inc., 1978), pp. 127-58.
101. Salk, J. and Salk, P. --- Immunologic medicine: a perspective. *Behring Inst. Mitt.* 63: 211-13, 1979.
- 102a. Salk, J., Westall, F. C., Romine, J. S., and Wiederholt, W. C. --- Preliminary phase studies of myelin basic protein in multiple sclerosis: I. Rationale and immunologic observations. *Neurology* 29(4): 573 (abstract), 1979.
- 102b. Romine, J. S., Salk, J., Wiederholt, W. C., Westall, F. C., Jablecki, C.K. --- Preliminary phase studies of myelin basic protein in multiple sclerosis: II. Clinical observations. *Neurology* 29(4): 572 (abstract), 1979.

103. Salk, J. --- The spector of malignancy and criteria for cell lines as substrates for vaccines. In *Cell Substrates: Their Use in the Production of Vaccines and Other Biologicals*, J. Petricciani, H. E. Hopps, P. J. Chapple, eds. (New York: Plenum Press, 1979), pp. 107-13.
104. Salk, J. --- Immunization against poliomyelitis: risk/benefit/cost in a changing context. *Dev. Biol. Stand.* 43: 151-57, 1979.
105. Salk, J., Romine, J. S., Westall, F. C., and Wiederholt, W. C. --- Myelin basic protein studies in experimental allergic encephalomyelitis and multiple sclerosis: a summary with theoretical considerations of multiple sclerosis etiology. In *The Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis*, A. N. Davison and M. L. Cuzner, eds. (London: Academic Press, 1980), pp. 141-56.
106. Salk, J. --- A theory of multiple sclerosis etiology. In *Search for the Cause of Multiple Sclerosis and Other Chronic Diseases of the Central Nervous System*, A. Boese, ed. (Weinheim: Verlag Chemie, 1980), pp. 470-76.
107. Salk, J., Westall, F. C., Romine, J. S., and Wiederholt, W. C. --- Studies on myelin basic protein administration in multiple sclerosis patients. 1. Rationale and preliminary report of immunologic observations. In *Progress in Multiple Sclerosis Research*, H. J. Bauer, S. Poser, G. Ritter, eds. (Berlin: Springer-Verlag, 1980), pp. 419-27.
108. Romine, J. S., Salk, J., Wiederholt, W. C., Westall, F. C., and Jablecki, C.K. --- Studies on myelin basic protein administration in multiple sclerosis patients. 2. Preliminary report of clinical observations. In *Progress in Multiple Sclerosis Research*, H. J. Bauer, S. Poser, G. Ritter, eds. (Berlin: Springer-Verlag, 1980), pp. 428-33.
109. Mered, B., Albrecht, P., Hopps, H. E., Petricciani, J. C., and Salk, J. --- Monkey kidney cell growth optimization and poliovirus propagation in microcarrier culture. *Dev. Biol. Stand.* 47: 41-53, 1981.
110. Salk, J., van Wezel, A. L., Stoeckel, P., van Steenis, G., Schlumberger, M., Meyran, M., Rey, J.-L., Lapinleimu, K., Bottiger, M., and Cohen, H. --- Theoretical and practical considerations in the application of killed poliovirus vaccine for the control of paralytic poliomyelitis. *Dev. Biol. Stand.* 47: 181- 98, 1981.
111. Mered, B., Albrecht, P., Hopps, H. E., Petricciani, J. C., and Salk, J. --- Propagation of poliovirus in microcarrier cultures of three monkey kidney cell lines. *J. Biol. Stand.* 9: 137- 45, 1981.

112. Salk, P. L., Wegemer, D. E., Ward, E. N., McClure, J. E., Goldstein, A.L., Romine, J. S., and Salk, J. --- Decreased circulating T lymphocytes and increased serum thymosin 1 levels in patients with chronic progressive multiple sclerosis. *Fed. Proc.* 41(3): 808 (abstract 3145), 1982.
113. Petricciani, J. C., Salk, P. L., Salk, J., and Noguchi, P. D. --- Theoretical considerations and practical concerns regarding the use of continuous cell lines in the production of biologics. *Dev. Biol. Stand.* 50: 15-25, 1982.
114. van Wezel, A. L., van der Marel, P., Van Beveren, C. P., Verma, I., Salk, P., and Salk, J. --- Detection and elimination of cellular nucleic acids in biologicals produced on continuous cell lines. *Dev. Biol. Stand.* 50: 59-69, 1982.
115. Salk, J., Stoeckel, P., van Wezel, A. L., Lapinleimu, K., and van Steenis, G. --- Antigen content of inactivated poliovirus vaccine for use in a one- or two-dose regimen. *Ann. Clin. Res.* 14(5-6): 204-12, 1982.
116. Salk, J. --- Immune response and minimum requirement for immunity to disease. *Scand. J. Infect. Dis. (suppl.)* 36: 65-67, 1982.
117. Salk, J. --- Future prospects for vaccination against virus diseases. *Behring Inst. Mitt.* 71: 34-42, 1982.
118. Romine, J. S. and Salk, J. --- A study of myelin basic protein as a therapeutic probe in patients with multiple sclerosis. In *Multiple Sclerosis*, J. F. Hallpike, C. W. M. Adams, W. W. Tourtellotte, eds. (London: Chapman and Hall, 1983), pp. 621-30.
119. Salk, J. --- Experience with inactivated poliovirus vaccine: comparison between inactivated and attenuated poliovirus vaccines. *A Saude no Brasil* 1(1): 21-25, 1983.
120. Salk, J. --- The virus of poliomyelitis: from discovery to extinction. *JAMA* 250(6): 808-10, 1983.
121. Seil, F. J., Westall, F. C., Romine, J. S., and Salk, J. --- Serum demyelinating factors in multiple sclerosis. *Ann. Neurol.* 13(6): 644-67, 1983.
122. Salk, D. and Salk, J. --- Vaccinology of poliomyelitis. *Vaccine* 2(1): 59-74, 1984.
123. Salk, J. --- One-dose immunization against paralytic poliomyelitis using a noninfectious vaccine. *Rev. Infect. Dis.* 6(suppl. 2): S444-50, 1984.
124. Mandell, A. J. and Salk, J. --- Developmental fusion of intuition and reason: a metabiological ontogeny. In *Normality and the Life Cycle*, D. Offer and M. Sabshin, eds. (New York: Basic Books, 1984), pp. 302-14.

125. Salk, J. and Salk, P. L. --- An evolutionary approach to world problems. [Invited paper.] Fourth Extraordinary Session of the General Conference, United Nations Educational, Scientific and Cultural Organization (UNESCO), Nov. 23-Dec. 3, 1982, Paris. [Invited papers not published.]
126. Salk, D., van Wezel A. L., and Salk, J. --- Induction of long-term immunity to paralytic poliomyelitis by use of non-infectious vaccine. *Lancet* II(8415): 1317-21, 1984.
127. Salk, J. --- Contributions of bioscience to biotechnology. In *Biotechnology and Bioprocess Engineering*, T. K. Ghose, ed. (Delhi: Indian Institute of Technology, 1985), pp. 15-35.
128. Salk, J. --- The next evolutionary step in the ascent of man in the cosmos. *Leonardo*, 18(4): 237-42, 1985.
129. Salk, J. --- Health and lifestyle. *Health Matrix*, III(3): 3-7, 1985.
130. Salk, J. --- How vaccines work--principles and practices. In proceedings of the International Symposium on Advances in Immunization and Vaccine Production (Bogata, Colombia, 29 September-4 October 1985).
131. Salk, J. --- Poliomyelitis. In *Encyclopedia of Neuroscience*, Vol. II, G. Adelman, ed. (Boston: Birkhauser, 1987), pp. 957- 58.
132. West, B. J. and Salk, J. --- Human conduct and natural laws: laws of simple and complex systems. *Mondes en Developpement*, 14: 317-25, 1986.
133. West, B. J. and Salk, J. --- Complexity, organization and uncertainty. *Eur. J. Operational Res.* 30: 117-28, 1987.
134. Zanetti, M., Sercarz, E., and Salk, J. --- The immunology of new generation vaccines. *Immunol. Today*, 8(1): 18-25, 1987.
135. Salk, J. --- Toward worldwide eradication of poliomyelitis. *Int. Pediatr.* 1(3): 137-44, 1986.
136. Salk, J. and Drucker, J. --- Noninfectious poliovirus vaccine. In S. A. Plotkin and E. Mortimer, *Vaccines* (Philadelphia: W. B. Saunders, 1988), pp. 158-81.
137. Salk, J. and Zanetti, M. --- Next steps in the evolution of vaccinology. In *Progress in Vaccinology*, G. P. Talwar, ed. (New York: Springer-Verlag, 1989), pp. 451-466.
138. West, B. J. and Salk, J. --- Creativity as a distributed function. *J. Social Biol. Struct.* 11(1): 158-161, 1988.

139. Salk, J. --- Prospects for the control of AIDS through immunization of seropositive individuals. *Nature* 327(6122): 473-76, 1987.
140. Salk, J. --- Poliomyelitis vaccination: choosing a wise policy [commentary]. *Ped. Infect. Dis. J.* 6(10): 889-93, 1988.
141. Salk, J. --- Development and evaluation of a vaccine for human immunodeficiency virus (HIV) Infection. *Ann. Int. Med.*
142. Salk, J. --- The logic of the magic of vaccination. *New Engl. & Regional Allergy Procs.* 9(6): 689-692, 1988.
143. Salk, J. and Gersten, M. J. --- Prophylactic and therapeutic immunization against AIDS: theoretical considerations underlying a modified non-infectious whole virus approach. In *AIDS Vaccine: Research and Clinical Trials*, S Putney and D. Bolognesi, eds. (New York: Marcel Dekker, Inc., 1990), pp. 265-275.
144. Salk, J. --- An envelope-deficient noninfectious HIV immunogen for studies on the prevention of HIV infection and/or disease. *Human Retroviruses* 119: 293-302, 1990.
145. Swartz, T.A., Handsher, R., Stoeckel, P., Drucker, J., Caudrelier, P., van Wezel, A.L., Cohen, H., Salk, D. and Salk, J. --- Immunologic memory induced at birth by immunization with inactivated polio vaccine in a reduced schedule. *Eur. J. Epidemiol.* 5(2):143-145, 1989.
146. Drucker, J. and Salk, J. --- Poliovirus vaccines. In *Vaccines and Immunotherapy*, S. J. Cryz, ed. (New York: Pergamon Press, 1991), pp. 225-245.
147. Salk, J. --- The importance of HIV-specific CMI for the immunological control of HIV infection. *Quatrième Colloque Des Cent Gardes*, pp. 273-278, 1989.
148. Salk, J. --- Studies on HIV immunotherapy progress report. *Quatrième Colloque Des Cent Gardes*, pp. 313-317, 1989
149. Salk, J. --- Are booster doses of poliovirus vaccine necessary? *Vaccine* 8(5): 419-420, 1990.
150. Gibbs, Jr., C.J., Peters, R., Gravell, M., Johnson, B. K., Jensen, F. C., Carlo, D. J., and Salk, J. --- Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees. *Proc. Natl. Acad. Sci. USA* 88: 3348-3352, 1991.
151. Salk, J. --- Brightening prospects for the control of HIV/AIDS by immunological means. *Cinquième Colloque Des Cent Gardes*, pp. 219-220, 1990.

152. Salk, J. --- An evolutionary philosophy for our time. In *Living Philosophies: The Reflections of Some Eminent Men and Women of Our Time*. Clifton Fadiman, ed. (New York: Doubleday, 1990), pp. 238-244.
153. Salk, J. and Salk, P. L. --- An evolutionary approach to world problems. *World Affairs* 1: 5-10, 1990.
154. Salk, J. --- Prospects for AIDS vaccines: the need for clinical trials in human populations. --- *Vaccine* 9(11): 791, 1991.
155. Levine, A., Henderson, B., Groshen, S., Munson, K., Allen, J., Carlo, D., Burnett, K., Jensen, F., Ferre, F., Trauger, R., Abrahamson, J., Gersten, M., and Salk, J. --- Immunization of HIV-infected individuals with inactivated HIV immunogen. *Cinquième Colloque Des Cent Gardes*, pp. 247-250, 1990.
156. Slade, H., Turner, J., Abrams, C., Carlo, D., and Salk, J. --- Immunotherapy of HIV-seropositive patients: preliminary report on a dose-ranging study. *AIDS Research and Human Retroviruses* 8(8): 1329-31, 1992.
157. Salk, J. --- HIV Immunotherapy: what is the immunological objective to be achieved? *Septième Colloque Des Cent Gardes*, pp. 283-84, 1992.
158. Atlan, H., Gertsten, M., Salk, P., and Salk, J. --- Can AIDS be prevented by T-cell vaccination? *Immunology Today* 14(5): 200-202, 1993.
159. Salk, J., Bretscher, P. A., Salk, P. L., Clerici, M., and Shearer, G. M. --- A strategy for prophylactic vaccination against HIV. *Science* 260: 1269-71, 1993.
160. Salk, J., Bretscher, P., Salk, P., Clerici, M., and Shearer, G. --- Protection from HIV Infection or AIDS? (response to Miedema, et al. letter). *Science* 262: 1074-76, 1993.
161. Salk, J. --- Merging Intuition and Reason. *Technological Forecasting and Social Change* 26: 167-170, 1984. Excerpt from the author's book, *Anatomy of Reality* (New York:: Columbia University Press , 1983).
162. Salk, J. --- Jonas Salk, medical researcher [an interview]. In *A World of Ideas II*, Bill Moyers (New York: Doubleday, 1990) pp. 236-242.
163. Salk, J. --- Immunotherapy of HIV/AIDS: approaches and criteria for effectiveness. *Sixième Colloque Des Cent Gardes*, pp. 301-304, 1991.
164. Salk, J. --- A sense of responsibility. *Harvard Medical Alumni Bulletin* Fall: 19-21, 1991.

165. Salk, J. --- Are we being good ancestors? *World Affairs* 1(2): 16-18, 1992. [Based on Acceptance Address: Jawaharlal Nehru Award for International Understanding, 1977.]
166. Vaslin, B., Le Grand, R., Vogt, G., Benveniste, O., Gras, G., Roques, P., Stoeckel, P., Salk, P. L., Salk, J., and Dormont, D. --- Induction of humoral and cellular immunity to simian immunodeficiency virus: what are the requirements for protection? *Vaccine* 12(12): 1132-40, 1994.
167. Salk, J., Drucker, J., and Malvy, D. --- Noninfectious Poliovirus Vaccine. In *Vaccines*, 2nd Edition, S. A. Plotkin and E. A. Mortimer, eds. (Philadelphia: W.B. Saunders Company, 1994), pp. 205-27.
168. Atlan, H., Gersten, M. J., Salk, P. L., and Salk, J. --- Mechanisms of autoimmunity and AIDS: prospects for therapeutic intervention. *Res. Immunol.* 145: 165-83, 1994.
169. Salk, P. L. and Salk, J. --- Cell-mediated immunologic memory in prevention and treatment of HIV disease. *Research in Immunology* 145(8-9): 629-35, 1994. Overview of cytokine climate, CD8 T cells and therapies in AIDS, *ibid.*, pp. 717-20.
170. Salk, J. --- Man Unfolding. In *Biology in Human Affairs*. H. Boardman and S. A. Ross, eds. (Washington, DC: Voice of America, Forum Series, 1974), pp.322-329.

BOOKS

Salk, J. Man Unfolding (New York: Harper & Row, 1972)

Salk, J. The Survival of the Wisest (New York: Harper & Row, 1973)

Salk, J. and Salk, J. D. World Population and Human Values: A New Reality (New York: Harper & Row, 1981)

Salk, J. Anatomy of Reality: Merging of Intuition and Reason (New York: Columbia University Press, 1983; New York: Praeger, 1985).
